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INTRODUCTION
To ensure uniform stem cell engraftment after allo-
geneic transplantation, total body irradiation (TBI)-based
regimens usually include TBI given at a total dose of 1000 cGy
or greater, at a dose rate of 7 to 10 cGy/min, and in frac-
tionated (versus single-dose) schemas. However, allogeneic
transplantation with conventional myeloablative regimens
results in significant morbidity and mortality. For patients
undergoing HLA-matched related-donor transplantation,
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ABSTRACT
On the basis of observations of dog models and from earlier studies with humans, we hypothesized that a low-
dose (550 cGy) TBI-based conditioning regimen would result in sustained engraftment of HLA-matched sibling
peripheral blood stem cells (PBSC) with low treatment-related mortality (TRM) and low serious organ toxicity
if the TBI was given as a single dose and at a high dose rate. The regimen included 550 cGy TBI administered
as a single dose at 30 cGy/min and cyclophosphamide. Cyclosporine was given as GVHD prophylaxis. Twenty-
seven good-risk (acute leukemia in first remission and chronic-phase chronic myelogenous leukemia) and
53 poor-risk (other) patients were accrued. Complete donor engraftment occurred in 93% to 100% of evaluable
patients at each scheduled assessment and was durable through 4 years. Mixed chimerism (50% to 98% donor)
was observed in 9 patients (11%). Without further intervention, all patients had complete donor engraftment on
subsequent assessments. Graft failure did not occur. TRM through at least 2 years was 7% in the good-risk and
19% in the poor-risk diagnostic groups. Grade 4 (fatal) organ toxicity occurred in only 2 patients (2.5%). Other
causes of TRM included infection and GVHD. Median follow-up for the surviving patients was 1234 days
(range, 780-1632 days). Current status includes 39 patients (49%) alive and in complete remission, 2 alive in
relapse, and 39 dead. Relapse occurred in 15% of the good-risk group and 45% of the poor-risk group. The
Kaplan-Meier estimates of 3-year disease-free and overall survival of the good-risk group were 77% and 85%,
respectively, and of the poor-risk group were 34% and 36%, respectively. Low-dose (550 cGy), single-exposure
TBI given at a high dose rate with cyclophosphamide resulted in consistent durable engraftment of HLA-
matched sibling PBSC with a low risk of fatal organ toxicity and TRM.
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(IBMTR) reported a treatment-related mortality (TRM) of
21% to 54% depending on disease state [1]. Improvements
in supportive care and clinical practice may have reduced
TRM; however, results of a recent randomized trial in
which peripheral blood stem cells (PBSC) and bone marrow
(BM) stem cells were compared confirmed that TRM
remains a frequent complication of donor transplantation,
occurring in 21% to 30% of patients [2].
Historically, an objective of the conditioning regimen
for donor transplantation included ablation of the lymphoid
and myeloid cells of the recipient. Total dose, dose rate, and
number of exposures are 3 variables that determine the
myeloablative and lymphoablative potential and the toxicity
of TBI. Data on dog models demonstrated that the total
dose of TBI required for lymphoablation was greater than
that required for myeloablation. When TBI was adminis-
tered at a standard dose rate of 10 cGy/min, a threshold
dose of 600 cGy uniformly ablated autologous marrow [3],
whereas 920 cGy was required for sustained allogeneic
engraftment [4]. The higher dose of TBI required to
achieve lymphoablation in the allogeneic setting is associ-
ated with a greater risk of toxicity.
Observations of dog models provide insight into poten-
tial strategies that could reduce toxicity of the TBI compo-
nent of the conditioning regimen. Both single-dose and
fractionated TBI schemas have comparable myeloablative
potential [3]. However, single-dose TBI is more immuno-
suppressive than is fractionated TBI at equal total doses and
dose rates [5]. Conceptually, a single-dose TBI regimen for
donor transplantation may allow use of a lower total TBI
dose, which could reduce the risk of toxicity.
For comparisons of single-dose TBI regimens of equal
total doses administered at either a high or a low dose rate, the
high-dose-rate approach is more immunosuppressive. With
dog models, Storb et al observed that 450 cGy of TBI deliv-
ered as a single exposure at a high dose rate of 70 cGy/min
resulted in sustained engraftment of stem cells obtained from
DLA-identical littermates. The same regimen given at a low
dose rate of 7 cGy/min failed to achieve this goal [6]. Impor-
tant is that the former TBI regimen was associated with infre-
quent organ toxicity and graft-versus-host disease (GVHD),
even though no GVHD prophylaxis was administered. These
data support the hypothesis that a low-dose TBI regimen can
result in sustained allogeneic stem cell engraftment with low
toxicity if given at a high dose rate and as a single dose.
In this study, we evaluated a low-dose, high-dose-rate,
single-exposure TBI-based regimen for HLA-matched
related-donor transplantation. This preparative regimen
was inspired by experience in the treatment of patients at
the University of Toronto [7] and was developed on the
basis of observations of dog models [3-6]. The regimen
included cyclophosphamide (60 mg/kg per day on days –3
and –2) and 550 cGy TBI administered on day –1 in a sin-
gle dose at 30 cGy/min. This dose rate of TBI was the max-
imum that could be administered by the institutional linear
accelerator. Because this dose rate was lower than that used
in the dog model observed by Storb et al [6], a higher total
dose of TBI was used in this study. A total dose of TBI less
than 600 cGy was selected because this dose was previously
demonstrated to be a threshold dose above which unaccept-
ably high rates of interstitial pneumonitis occurred in
patients who received single-dose upper hemibody irradia-
tion at similar dose rates [8]. We hypothesized that this
conditioning regimen would result in sustained donor stem
cell engraftment, low TRM, a low rate of serious organ tox-
icity, and an acceptable relapse risk.
METHODS
Patient Eligibility
Patients with the following diagnoses were eligible:
acute myeloid (AML) or lymphoid (ALL) leukemia in ﬁrst
complete remission (CR) associated with high risk of relapse
or with relapsed disease; chronic myelogenous leukemia
(CML) in chronic or accelerated/acute phase; myelodyspla-
sia (MDS), including therapy-related or refractory anemia
with excess blasts, poor-risk cytogenetic abnormalities,
and/or severe neutropenia/thrombocytopenia; poor-risk
non-Hodgkin’s lymphoma (NHL), including failure to
achieve CR after primary therapy, less than a partial
response to salvage therapy for relapse, or persistent
involvement of peripheral blood by lymphoma; chronic
lymphocytic leukemia (CLL) with failure to respond to con-
ventional therapy; relapsed multiple myeloma; and myeloﬁ-
brosis. Patients with acute leukemia in ﬁrst CR and at high
risk of relapse were defined as those with adverse cytoge-
netic abnormalities [–5/5q-, –7/7q-, 11q23 abnormalities,
t(4,11), t(9,22), or complex (≥3) abnormalities] or need for
reinduction chemotherapy to achieve first CR. Exclusion
criteria included performance status >2 (Eastern Coopera-
tive Oncology Group), left ventricular ejection fraction
<40% of predicted value, diffusion lung capacity of carbon
monoxide or forced expiratory volume in 1 second <45% of
predicted value, serum creatinine level >3.0 mg/dL or meas-
ured creatinine clearance <25 mL/min, serum transaminase
levels >5 times the upper limits of normal, or positive result
of a pregnancy test. Donors were siblings matched at the
HLA A, B, and DR sites and met other criteria for donation
of stem cells as previously defined [9]. The study was
approved by the institutional review board of Washington
University School of Medicine, and all patients and donors
gave written informed consent.
Conditioning Regimen
The conditioning regimen included cyclophosphamide
60 mg/kg per day and methylprednisolone 1 g per day both
given on transplantation days –3 and –2, followed by 550 cGy
of TBI administered in a single dose at 30 cGy/min (±15%)
on day –1. The mean actual dose rate was 31.7 cGy/min
(range, 26.4-36.0 cGy/min). The TBI was delivered in paral-
lel opposed lateral ﬁelds with 6-MeV photons with a Clinac
600 CD accelerator (Varian Medical Systems, Alpharetta,
GA). Patients were in a sitting position and were treated with
a 300-cm source to midline distance. The point of dose pre-
scription was a single point midline in the body at the level of
the umbilicus. A large Lucite plate was placed near the
patient to enhance the skin dose, and a tissue compensator
was used to keep the midline dose to the head and neck to
within 110% of the prescription dose. Both ion chamber and
diode placed on different parts of the body were used to
ensure that the measured and calculated doses were within
acceptable limits.
W. Blum et al.
610
Mobilization and Collection of Donor Stem Cells
Growth factor mobilization included granulocyte
colony-stimulating factor (G-CSF) (10 µg/kg per day) alone,
G-CSF (10 µg/kg per day) plus granulocyte-macrophage
CSF (GM-CSF) (5 µg/kg per day), or GM-CSF (10 µg/kg
per day) alone given to 61, 10, and 9 donors, respectively.
PBSC collection by leukapheresis began on the ﬁfth day of
growth factor treatment and was performed as previously
described [9]. The target of CD34+ cells was 2.0 × 106
CD34+ cells per kilogram actual recipient body weight to be
collected in no more than 3 aphereses. Growth factors were
stopped on the last day of apheresis. T-cell depletion and
cryopreservation of allogeneic PBSCs were not performed.
PBSCs were collected and transplanted without manipula-
tion on day 0.
GVHD Prophylaxis and Treatment
GVHD prophylaxis included cyclosporine alone given as
an oral dose of 6.25 mg/kg every 12 hours beginning on day
–2. Patients unable to take cyclosporine orally received the
drug by the intravenous (IV) route at a dose of 3 mg/kg per
day (as a 4-hour infusion in 2 divided doses) until they were
able to tolerate the oral formulation. Trough cyclosporine
levels were measured at least twice weekly, and dose adjust-
ments were made to achieve the desired drug level of 200 to
400 ng/mL. Between day +100 and month 6 posttransplanta-
tion, cyclosporine was tapered at a rate of approximately 5%
per week in those patients without active GVHD.
Acute GVHD was graded according to the scheme of
Glucksberg et al. [10], and chronic GVHD was graded
according to that of Shulman et al. [11]. Diagnosis of GVHD
was based on clinical manifestations and results of histologic
examination of biopsy specimens of affected tissues. Acute
GVHD of grade 2 or higher was treated with methylpred-
nisolone at a dose of 2 mg/kg per day. Chronic GVHD was
treated with cyclosporine, prednisone, and/or azathioprine
(25 to 150 mg/day on the basis of myelosuppression).
Supportive Care
Mesna and hydration were administered as prophylaxis
against cyclophosphamide-induced hemorrhagic cystitis.
Administration of G-CSF (10 µg/kg per day subcuta-
neously) began on day +1 and continued until the absolute
neutrophil count (ANC) exceeded 1500/µL for 2 consecu-
tive days after the nadir ANC. Blood product support
included prophylactic transfusion of 1 unit of single-donor
irradiated platelet components for a platelet count of
<10,000/µL and of 2 units of packed red blood cells (PRBC)
for hemoglobin <8 g/dL. Prophylactic granulocyte compo-
nents mobilized with G-CSF were collected from the PBSC
donor and transfused on days +5 and +7, as previously
described [12], if the donor was ABO compatible with the
recipient and met standard criteria for donation of granulo-
cyte components. Granulocyte components were collected
from 39 of the 80 donors, irradiated, and freshly transfused
into the respective patient on the day of collection.
Prophylactic acyclovir was administered to all patients.
Prophylactic antibacterial or antifungal agents were not
used. Initial empiric therapy for febrile neutropenia
included imipenem/cilastatin with the subsequent addition
of vancomycin or amphotericin-B for suspected catheter-
related infection or fungal infection, respectively. Docu-
mented bacteremia, sepsis syndrome, and tissue infection
(eg, pneumonia) were treated with a 14-day course of appro-
priate IV antimicrobial agents. On engraftment and until
day +150, surveillance testing of blood for cytomegalovirus
(CMV) was performed every 2 weeks by routine viral and
shell vial culture of buffy coat specimens. Positive CMV test
results in the absence of signs or symptoms of CMV disease
were treated with ganciclovir 5 mg/kg IV daily for 21 days.
CMV disease was treated with ganciclovir 5 mg/kg twice
daily for 21 days and immune globulin 500 mg/kg IV every
other day ( 7 doses).
Evaluation, Endpoints, and Statistics
Pretransplantation disease status was defined as CR1,
≥CR2, or relapse according to the results of appropriate
staging studies (eg, BM aspirate, radiographic tests). Post-
transplantation evaluations were performed on days +30,
+100, and +180, 1 year after transplantation, and yearly
thereafter. Each evaluation included an assessment of mar-
row chimerism, disease status (CR or relapse), survival status
(alive or dead), treatment-related toxicity and TRM, and
GVHD (grade).
Chimerism was assessed with variable number of tandem
repeat (VNTR) probes as described previously [13,14]. In
brief, DNA was isolated from white blood cells from pre-
transplantation donor and recipient peripheral blood samples
and posttransplantation recipient BM was collected in
sodium EDTA tubes with a modiﬁed salting-out procedure
(Puregene DNA Isolation Kit, Gentra Systems, Minneapolis,
MN) with ﬂuorometric quantitation of the DNA. Genomic
DNA digests (5 µg each) were prepared with either Hinf 1 or
Alu1 restriction endonuclease (10 units per µg DNA) and
buffer conditions as recommended by the manufacturer
(New England Biolabs, Beverly, MA). After electrophoretic
separation on 0.8% agarose gels, the DNA was transferred to
nylon membranes under alkaline conditions (Zeta-Probe,
BioRad, Hercules, CA) [13]. These genomic Southern blots
were hybridized to radiolabeled, hypervariable minisatellite
repeat probes D1S7, D1S8, D5S43, and D7S22 [14] with
Quickhyb (Stratagene, La Jolla, CA) in a Hybaid oven
(National Labnet, Woodbridge, NJ). Filters were exposed to
x-ray ﬁlm (X-OMAT, Kodak Rochester, NY) with intensiﬁer
screens at –70°C and visually examined for either informa-
tive patterns (in the pretransplantation samples) or evidence
of complete engraftment and/or mixed chimerism (in the
posttransplantation samples). Sensitivity of detection by this
method was 1% to 5%. One informative marker was selected
for study of posttransplantation engraftment patterns in all
follow-up specimens.
The endpoints of the study were donor cell engraftment
rate, treatment-related toxicity, TRM, GVHD, and survival.
Engraftment was deﬁned as complete if marrow cells were
only of donor origin as determined by VNTR probes or as
mixed if marrow cells were of donor and host origin. Primary
graft failure was defined as persistent neutropenia (ANC
<500/µL) through day +30 with no evidence of engraftment
of donor cells. Secondary graft failure was deﬁned as the ini-
tial occurrence of neutrophil engraftment (postnadir ANC
>1500/µL for 2 consecutive days) of donor origin followed by
the development of otherwise unexplained neutropenia (ANC
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<500/µL for at least 3 consecutive days) in association with
loss of evidence of donor cell engraftment. Patients with
relapsed disease were not evaluable for engraftment or graft
failure at the time of or after relapse.
Treatment-related organ toxicity was graded with the
National Cancer Institute (NCI) Cancer Therapy Evalua-
tion Program (CTEP) criteria for autologous BM transplan-
tation (BMT) studies. Grade 0 indicated no toxicity, grade 4
was fatal toxicity, and grades 1 through 3 were increasing
levels of toxicity [15]. Idiopathic interstitial pneumonitis was
deﬁned as bilateral interstitial pulmonary inﬁltrates associ-
ated with dyspnea, shortness of breath, and hypoxemia
occurring after transplantation and in which no infectious
etiology could be defined by culture of pulmonary tissue/
secretions or blood. Cases in which pulmonary infiltrates
developed in association with sepsis syndrome (fever with
hypotension) but with negative culture results were scored
as infectious pneumonia and were presumed due to a bacter-
ial etiology. TRM was deﬁned as death of all causes occur-
ring after transplantation except relapse of disease. Patients
who died before neutrophil engraftment without evident
GVHD were not evaluable for acute GVHD. Patients who
either died or who had relapses before day +100 were not
evaluable for chronic GVHD.
Relapsed disease was defined as morphologic or radio-
graphic evidence of disease occurring at any single post-
transplantation evaluation. CML with only cytogenetic
evidence of the CML clone at a single posttransplantation
evaluation was not scored as relapsed disease if the BM and
peripheral blood morphology were normal, if all subse-
quent evaluations failed to demonstrate cytogenetic evi-
dence of the CML clone, and if no active therapeutic
intervention (including donor lymphoid infusion, inter-
feron, or second transplantation) was instituted.
Both disease-free survival (DFS) and overall survival
(OS) were assessed with the Kaplan-Meier (KM) technique
[16] and were determined from the day of transplantation
(day 0). Patients were censored for DFS if they were alive
and in remission at last follow-up evaluation. Patients were
censored for OS if they were alive at last follow-up evalua-
tion. Follow-up was through February 28, 2002. Data analy-
sis was performed with the StatView program (version 4.5,
Abacus Concepts, Berkeley, CA).
RESULTS
Patient and PBSC Characteristics
Eighty patients were accrued to this study, and all
received the conditioning regimen followed by transplanta-
tion of allogeneic PBSC. The mean age was 46 years, and
patients up to 68 years were included (Table 1). Thirty-two
patients (40%) were ≥50 years of age. The majority of
patients had acute and chronic leukemia or NHL. Twenty-
seven patients (34%) were classiﬁed in the good-risk diag-
nostic group and 53 (66%) in the poor-risk group. The
median follow-up period for living patients was 1234 days
(range, 780-1632 days). The mean numbers of CD34+ PBSC
and CD3+ PBSC transplanted were 6.77 ( 106 (range, 0.39-
46.5  106) and 18.85  107 (range, 2.7-100.7  107) cells
per kilogram, respectively.
Chimerism and Graft Failure
Nearly all patients had complete donor cell engraftment
in the BM at each of the time points assessed posttransplan-
tation (Table 2). The percentages of evaluable patients with
complete donor engraftment at days +30, +100, and +180,
Table 1. Patient Characteristics*
No. of Patients 80
Mean age, y 46 (17-68)
Diagnosis, no. of patients
AML 16
ALL 6
MDS 10
CML 22
NHL 22
Myeloma 2
CLL 1
Myelofibrosis 1
Diagnostic risk group†
Good 27
Poor 53
Median follow-up period for living patients, days 1234 (780-1632)
*Values in parentheses are ranges.
†Good indicates acute leukemia in CR1 with adverse cytogenetics
and CML in chronic phase; poor, acute leukemia in relapse or ≥CR2,
CML in accelerated/acute phase, MDS, NHL, multiple myeloma,
CLL, or myeloﬁbrosis.
Table 2. Marrow Chimerism
No. of Patients with the Following Percentage of Donor Cells
Transplantation Day 100%* 90%-99% 50%-89% 0% No. of Nonevaluable Patients†
+30 68 2 1 0 9
+100 51 2 2 0 25
+180 44 1 1 0 34
Year 1 41 1 1 0 37
Year 2 34 0 0 0 46
Year 3 23 0 0 0 57
Year 4 7 0 0 0 73
*Limit of detection by VNTR method used was ≥1% recipient cells.
†Nonevaluable because of relapse, death, test not done, or short follow-up period.
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year 1, and years 2 to 4 posttransplantation were 96%, 93%,
96%, 95%, and 100%, respectively. Primary or secondary
graft failure did not occur.
Mixed chimerism was observed in 9 patients (11%) in at
least 1 of the time points assessed posttransplantation (Table 3).
On day +30, 3 patients had mixed chimerism (80%-98%
donor cells). One of these patients (unique patient number
[UPN] 14) had persistent CLL, and 2 patients were in CR.
Without further treatment, all 3 of these patients had com-
plete donor chimerism on subsequent assessments. At last
follow-up evaluation, UPN 14 was alive on day +1632 and in
CR, UPN 26 had died of leukemic relapse on day +361, and
UPN 55 was alive on day +1516 and in CR. After day +30,
5 patients with CML had mixed chimerism (50%-99% donor
cells) at a single scheduled assessment. Two of these patients
had normal cytogenetic results, and 3 had cytogenetic but not
histologic evidence of disease. Without further treatment, all
of these patients had complete donor chimerism on subse-
quent assessments performed within 6 months. Of the
3 CML patients with mixed chimerism and only cytogenetic
evidence of disease, all had complete donor chimerism and
normal cytogenetic results on subsequent assessments per-
formed within 6 months. No active therapeutic intervention
was performed at the time of cytogenetic evidence of disease
other than a reduction in the dose of immunosuppressive
agents. These patients were alive and in cytogenetic CR.
Treatment-Related OrganToxicity
The treatment regimen was associated with a low inci-
dence (2 of 80 patients [2.5%]) of serious (NCI grade 4 or
fatal) organ toxicity (Table 4). One patient experienced
grade 4 cardiac toxicity (asystole) on day +606 but before
transplantation had a history of arrhythmias due to extensive
cardiac involvement by NHL. One patient experienced
grade 4 cyclosporine-induced neurotoxicity that manifested
as seizure and central nervous system (CNS) hemorrhage.
In the other 78 patients, the regimen was generally well tol-
erated with a low incidence of NCI grade 3 organ toxicity.
Overall, only 4 patients (5%) experienced any mucositis (all
grade 1). Grade 3 hepatic and bladder toxicity did not occur,
and no patient needed hemodialysis. Idiopathic pneumonitis
did not occur. Seizure due to cyclosporine neurotoxicity
occurred in 3 other patients, all of whom had no sequelae
(grade 3). One other patient had nonfatal CNS hemorrhage
associated with thrombocytopenia (grade 3).
Infection
Deaths due to infection occurred in 9 patients (11.3%).
Infection-related pneumonia developed in 13 patients
(16%). Eight of the cases of pneumonia occurred in the con-
text of treatment of GVHD. Six of the 13 patients (7.5%
overall) died with pneumonia as a related or proximate cause
of death, and 7 patients recovered. Causes of pneumonia
included bacteria alone (8 patients), bacteria and fungus
(2 patients), CMV alone (1 patient) or with fungus (1 patient),
and nocardiae and parainﬂuenza virus (1 patient).
Table 3. Patients with Mixed Chimerism*
Unique
Chimerism, % Donor Cells
Patient Day Day Day Year Year Year Year Status at Last
Number Diagnosis +30 +100 +180 1 2 3 4 Disease Status Follow-up Evaluation
26 AML (CR1) 90 100 100 — — — — CR until relapse on day +313 Died, day +361
14 CLL 80 80 ND 100 100 100 ND Partial remission days +30 Alive in CR, day +1632 
and +100, CR day +180
55 MDS 98 90 100 100 100 100 100 CR Alive in CR, day +1516
33 CML 100 70 100 100 100 100 — CR (by cytogenetics) at each Alive in cytogenetic CR, day +1247 
assessment
1 CML 100 100 50 100 100 100 — Cytogenetic relapse only on Alive in cytogenetic CR, day +1556 
day +180, CR (by cytogenetics) 
years 1-3
61 CML 100 100 95 ND 100 100 — CR (by cytogenetics) at each Alive in cytogenetic CR, day +1006 
assessment
7 CML 100 100 100 80 100 100 100 Cytogenetic relapse only year 1, Alive in cytogenetic CR, day +1611 
CR (by cytogenetics) years 2-4
31 NHL 100 100 100 95 100 100 — CR Alive in CR, day +1234
20 CML 100 99 100 100 100 100 — Cytogenetic relapse only on Alive in cytogenetic CR, day +1253
day +859, CR (by cytogenetics) 
year 3
*ND indicates not done.
Table 4. Treatment-Related Organ Toxicity
No. of Patients Who Developed
Toxicity NCI Grade*
Organ 1 2 3 4 (Fatal)
Oral mucosa 4 0 0 0
Hepatic 35 11 0 0
Bladder 7† 0 0 0
Renal 0 35 2 0
Idiopathic pneumonitis 0 0 0 0
Cardiac 0 1 0 1
CNS 0 1 4 1
*NCI CTEP criteria for autologous BMT studies [15].
†Five cases were associated with BK Polyomavirus infection.
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Fungal infections of the tissue or blood were docu-
mented in 5 patients (6%), all of whom had acute GVHD.
Four of these patients died, 2 of whom were grouped earlier
as having infection-related pneumonia. One other patient
died of sepsis syndrome. Only 2 patients (2.5%) developed
CMV disease (pneumonia).
Graft-versus-Host Disease
Of the 79 patients evaluable for acute GVHD, 6 (8%)
and 41 (52%) patients developed grades 1 and 2 acute
GVHD, respectively, whereas only 6 patients (8%) devel-
oped grade 3 or 4 acute GVHD. Fifty-nine patients were
evaluable for chronic GVHD. Limited and extensive
chronic GVHD occurred in 1 patient (2%) and 49 (83%)
patients, respectively. One patient died of chronic GVHD
on day +922 posttransplantation.
Hematologic Recovery, Febrile Days, Hospital Stay
The median posttransplantation times to recovery of an
ANC >500/µL and platelet count >20,000/µL were 9 days
(range, 4-13 days) and 12 days (range, 5-75 days), respec-
tively. The median numbers of PRBC and single-donor
platelet components transfused per patient were 3 (range,
0-10) and 2 (range, 0-12), respectively. Eight patients did
not need PRBC transfusion, and 7 did not need platelet
transfusion. During hospitalization for transplantation, the
median number of febrile (≥38.3°C) days was 3 (range, 0-15),
and the median duration of use of IV antibiotics was 9 days
(range, 0-37 days). During this interval, 27 patients (34%)
did not experience febrile days, and 16 (20%) did not need
IV antibiotics. The median length of stay (LOS) during
the initial hospitalization for the transplantation procedure
was 18 days (range, 4-33 days), and the mean LOS through-
out the first 100 days posttransplantation was 23 days
(range, 4-60 days).
Survival, TRM, and Relapse
The median follow-up for living patients was 1234 days
(range, 780-1632 days) posttransplantation. Thirty-nine
patients (49%) were alive and in CR at last follow-up evalu-
ation, and 2 patients were alive with relapsed disease.
Thirty-nine patients (49%) died (Table 5), 26 patients (33%)
of relapsed disease and 1 patient of a drug (narcotic) over-
dose. With a minimum follow-up of 2 years for living
patients, the overall TRM was 15% (12 patients). By risk
group, the TRM was only 7% (2 patients) in the good-risk
diagnostic group and was 19% (10 patients) in the poor-risk
group. TRM was due to organ toxicity in 2 patients, exten-
sive refractory chronic GVHD in 1 patient, and infection in
9 patients. TRM occurred in association with acute GVHD
in 7 of these patients.
Relapse of disease occurred in 28 patients (35%), includ-
ing 4 patients (15%) in the good-risk diagnostic group and
24 patients (45%) in the poor-risk group. The 3 patients with
CML (UPN 1, 7, and 20) with transient mixed chimerism
and transient cytogenetic evidence of the CML clone were
not scored as having a relapse because this evidence was
found at a single evaluation. All subsequent evaluations failed
to demonstrate cytogenetic evidence of the CML clone, and
other than lowering the dose of immunosuppressive agents,
no active therapeutic intervention was instituted.
The KM estimates of DFS and OS for patients in each
diagnostic risk group are shown in Figures 1 and 2. The KM
estimates of 3-year DFS and OS of the 27 patients in the
good-risk diagnostic group were 77% and 85%, respectively.
The KM estimates of 3-year DFS and OS of the 53 patients
in the poor-risk group were 34% and 36%, respectively.
DISCUSSION
Reducing treatment-related toxicity and mortality is an
important objective in clinical trials attempting to improve
outcome among patients undergoing donor transplantation.
Recently, several groups evaluated nonmyeloablative condi-
tioning regimens as novel strategies to reduce treatment-
related toxicity. Both purine analogue-based regimens and a
regimen of 200 cGy of single-dose TBI given with cyclo-
sporine and mycophenolate mofetil were initially reported to
be well tolerated [17,18]. However, subsequent reports that
included larger numbers of patients noted that the risks of
TRM and serious organ toxicity with these regimens were
not inconsequential [19-22]. No comparative analysis has
been performed to determine whether the toxicity and TRM
of these regimens are actually lower than those of conven-
tional regimens. Initial reports of nonmyeloablative regimens
described an approximate 20% risk of graft rejection and a
high risk of relapse in patients with poor-risk diagnoses. This
finding prompted changes, including intensification of the
conditioning regimen and administration of donor lymphoid
infusions. These changes would be expected to increase the
toxicities of such regimens. Modifications of conventional
myeloablative conditioning regimens designed to reduce
treatment-related toxicity and mortality may be a strategy
with a lower risk of graft rejection and a higher chance of
early complete donor chimerism than is associated with non-
myeloablative regimens. Such low-toxicity myeloablative
regimens may be particularly suited for patients with poor-
risk diagnoses who have a high risk of disease relapse with
nonmyeloablative regimens and a high risk of TRM with
conventional myeloablative regimens.
In this study, we hypothesized that a low-dose TBI-based
conditioning regimen for patients undergoing donor trans-
plantation would result in sustained allogeneic stem cell
engraftment with a low risk of fatal organ toxicity and TRM,
if the TBI were given as a single dose and at a high dose rate.
The regimen was based on the conventional myeloablative
regimen of cyclophosphamide and TBI [23], but the TBI was
modiﬁed and given as a single, low (550 cGy) dose at a high
dose rate (30 cGy/min). The TBI dose was approximately
half the total dose used in conventional regimens for donor
transplantation, whereas the dose rate was 3 to 4 times stan-
dard. When we used this low-dose TBI-based regimen, we
observed complete engraftment of HLA-matched related
donor cells in ≥93% of evaluable patients at each of the time
points that chimerism was assessed. Engraftment of donor
cells was durable given that complete donor engraftment
extended through 4 years posttransplantation. Graft failure
did not occur. In contrast, nonmyeloablative regimens for
HLA-matched related donor transplantation resulted in
graft rejection in up to 20% of patients and in early mixed
(versus complete donor) chimerism in most of the other
patients. Sandmaier et al. reported median donor (T-cell)
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chimerism of 60% to 70% within the initial 56 days post-
transplantation after 200 cGy TBI (with or without ﬂudara-
bine), cyclosporine, and mycophenolate [24]. Childs et al.,
however, reported complete donor (T-cell) chimerism in
7 of 15 patients (46%) by 30 days posttransplantation after
use of ﬂudarabine and cyclophosphamide [25]. In the latter
study, subsequent cyclosporine withdrawal and donor lym-
phocyte infusions further increased the proportion of
patients with complete donor chimerism but were associated
with onset of acute GVHD. The correlative observations in
the studies by Childs et al. and others that complete donor
(T-cell) chimerism often preceded disease regression
[22,25,26] suggest that achievement of complete donor
chimerism posttransplantation is very important in predict-
ing clinical outcome. An intuitive conclusion is that achiev-
ing complete donor chimerism early (versus late) would be
expected to beneﬁt a larger proportion of patients undergo-
ing donor transplantation. Unlike nonmyeloablative regi-
mens, the low-dose TBI-based regimen used in this study
resulted in complete donor cell engraftment in ≥93% of
evaluable patients as early as 30 days posttransplantation, a
proportion sustained at all subsequent time points that
chimerism was assessed. The rate of durable complete donor
engraftment could be different with the use of a more
aggressive approach to GVHD prophylaxis [27,28].
Overall, this low-dose TBI-based conditioning regimen
was associated with a low incidence of serious organ toxicity.
NCI grade 4 (fatal) organ toxicity occurred in only 2 patients
(2.5%). The low incidence (2.5%) of fatal regimen-related
organ toxicity in this study compares favorably with the
14.8% (12 of 81 patients) incidence of fatal organ toxicity
reported in recipients of G-CSF–mobilized, HLA-matched
related-donor PBSC given conventional myeloablative condi-
tioning regimens [2]. This ﬁnding suggested that use of allo-
geneic PBSC (versus BM) in our trial did not alone account
for the low incidence of serious organ toxicity observed. In
recipients of nonmyeloablative regimens, grade 4 (fatal) organ
toxicity occurred in 4 of 65 patients (6.1%) given 200 cGy
TBI (with or without fludarabine), cyclosporine, and
mycophenolate [19] and in 3 of 78 patients (3.8%) given
ﬂudarabine-based regimens [21]. The low risk of fatal organ
toxicity with these nonmyeloablative regimens is particularly
notable because many of these patients were reported to be
older or to have comorbid conditions pretransplantation.
Conventional myeloablative regimens for donor trans-
plantation result in significant TRM, primarily due to
regimen-related organ toxicity, infection, and GVHD. In
this study, the TRM through the minimum follow-up period
of more than 2 years posttransplantation was relatively low,
at 15% overall. Notable was that the 7% TRM observed in
the good-risk diagnostic group is within the range of TRM
reported for patients undergoing autologous transplantation
[29]. The relatively low TRM observed in this favorable
cohort may be due to the low frequency of fatal organ toxic-
ity (2.5%) and severe (grade 3-4) acute GVHD (8%).
Patients with poor-risk diagnoses are known to be at greater
risk of TRM after allogeneic transplantation than are
patients with good-risk diagnoses; however, the TRM of
19% observed in the poor-risk group in this study compares
favorably with the 26% TRM observed in comparable
patients treated at our institution with a conventional frac-
tionated TBI (1225 cGy)-based regimen [30] and with the
38% to 54% TRM reported by the IBMTR for similar
poor-risk patients undergoing HLA-matched related-donor
transplantation [1]. A recent randomized trial failed to
demonstrate a signiﬁcant difference in the incidence of TRM
in recipients of G-CSF–mobilized PBSCs versus BM (21%
versus 30%, respectively, P = .24) after conventional mye-
loablative conditioning regimens. This finding suggested
that the relatively low TRM observed in our study was not
due to the exclusive use of PBSC [2]. The TRM observed in
the poor-risk diagnostic group in this study also compares
favorably with the TRM associated with nonmyeloablative
conditioning regimens, reported to be 14.3% by the Seattle
group [24] but which varied between 9.5% and 33.3% in
other reports [17,25,26,31,32]. However, these studies of
nonmyeloablative regimens included many patients with
comorbidities or who were older than 50 years, and thus
direct comparisons with our study are difﬁcult to perform.
In murine BMT models, the incidence and severity of
GVHD increased with higher TBI doses [33,34]. Ferrara
et al. hypothesized that the higher TBI dose increased the
severity of GVHD through increased gut injury and resulted
in greater systemic levels of inﬂammatory cytokines [33,34].
In clinical studies, the frequency of grades 2 through 4
acute GVHD was greater in leukemia patients conditioned
with 1575 cGy of fractionated TBI (at 6-7 cGy/min) versus
1200 cGy [23,35]. Nash et al. observed that increased TBI
dose (0-1200 versus >1200 cGy) was a significant adverse
independent risk factor associated with grades 2 through 4
acute GVHD [36]. Whether the incidence and severity of
GVHD vary across lower TBI doses (<1200 cGy) is unclear;
however, the outcomes observed in our study support the
idea that this hypothesis could be true. In the current study,
GVHD prophylaxis included cyclosporine alone. Methotrex-
ate was excluded to avoid its potential adverse effects on the
gut mucosa and on the pace of engraftment. The frequency
of severe (grades 3-4) acute GVHD was only 8% and of
grades 1 through 4 acute GVHD was 68%. In another study,
patients with leukemia undergoing HLA-matched sibling
BMT after cyclophosphamide treatment and 1200 cGy frac-
tionated TBI (at 6.5 cGy/min) were randomized to receive
GVHD prophylaxis with methotrexate and cyclosporine ver-
sus cyclosporine alone [37]. The frequencies of severe and of
grades 1 through 4 acute GVHD in patients given cyclo-
sporine alone were 28% and 76%, respectively. Interesting
was that the frequency of severe acute GVHD in patients
given cyclosporine and methotrexate was only 7%. Thus the
frequency of severe acute GVHD observed in our patients
conditioned with 550 cGy of TBI appeared to be lower than
that observed in other studies of patients conditioned with
conventional-dose TBI-based regimens in which cyclo-
sporine alone was used as GVHD prophylaxis. The fre-
quency appeared to approximate that observed when
methotrexate and cyclosporine were used as GVHD prophy-
laxis. The very low frequency of mucositis observed in our
patients who also had a low frequency of severe acute
GVHD is intriguing because it is consistent with the hypoth-
esis of Ferrara et al. that gut injury is central to the propaga-
tion of inﬂammatory mediators of acute GVHD [34].
Extensive chronic GVHD occurred in 83% of evaluable
patients accrued to this study. Although the incidence of
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extensive chronic GVHD was high, only 1 patient died as a
result of this complication. However, this result may not
accurately reflect the study population’s true incidence of
death due to chronic GVHD, because competing events
such as relapse and TRM from other causes may have
decreased the number of patients who otherwise would have
died as a result of this complication. The incidence of death
due to chronic GVHD and therefore the overall TRM may
change with longer follow-up. The cause of the relatively
high incidence of chronic GVHD observed in our study
population is unclear. The high incidence could be a result
of an unrecognized effect of the TBI regimen used in this
study or the use of PBSC (versus BM). The latter issue
remains controversial [2,30,38,39].
An important challenge in developing lower-intensity,
less toxic conditioning regimens for donor transplantation is
to ensure that any potential gain by reduction in the TRM is
not offset by an increased relapse risk. Previous studies have
shown that the leukemic relapse rate associated with
1200 cGy of fractionated TBI is higher than that with
1575 cGy of TBI; however, the overall beneﬁt of the latter
was offset by the greater TRM among patients given the
higher dose of TBI [23,35]. In this study, with a minimum
follow-up of more than 2 years in living patients, relapse
occurred in only 15% of patients in the good-risk diagnostic
group and in 45% of the poor-risk group. These outcomes
compare favorably with that observed in patients condi-
tioned with conventional TBI regimens for donor trans-
plantation and with the high risk of early leukemia relapse
or progression in poor-risk patients conditioned with non-
myeloablative regimens [17]. For patients with AML in ﬁrst
CR and CML in chronic phase undergoing HLA-matched
sibling BMT and conditioned with fractionated TBI
(1200 cGy at 6-7 cGy/min) and cyclophosphamide, Clift et
al. reported the risks of relapse were 35% and 25%, respec-
tively [23,35]. The risk of relapse for patients with leukemia
not in ﬁrst remission who underwent HLA-matched sibling
BMT after fractionated TBI (1320 cGy) and etoposide
treatment was 44% [40]. For patients conditioned with frac-
tionated TBI (1020 cGy), cyclophosphamide, and etoposide,
the risk of relapse was 69% [41]. Limitations of our study
include relatively short follow-up, small patient numbers in
each diagnostic risk group, and single-institution experi-
ence. Use of PBSC (versus BM) was reported to be associ-
ated with a reduced relapse risk (14% versus 25%, P = .04)
in a prospective, randomized study of both good- and poor-
risk patients and thus may also confound comparison of our
results with those reported in the literature [2]. Finally, in
our study, the relatively high rates of extensive chronic and
grade 2 acute GVHD, both of which have been associated
with lower relapse rates [42], did not clearly translate into
improved rates of long-term disease control in the patients
with poor-risk diagnoses. However, the latter was a hetero-
geneous group. Further studies will be required to deter-
mine the signiﬁcance of this observation.
In this study, the KM estimates of 3-year DFS and OS
for patients in the good-risk diagnostic group were 77% and
85%, respectively, and in the poor risk group were 34% and
36%, respectively. Given the minimum follow-up of more
than 2 years for living patients, all surviving patients remain
at risk of disease relapse and death; however, these prelimi-
nary outcomes compare favorably with those reported for
similar patients conditioned with conventional TBI-based
regimens for donor BMT or PBSC transplantation. For
Table 5. Causes of Death*
Cause of Death No. of Patients Who Died
TRM
Organ toxicity 2 (2.5)
Chronic GVHD 1 (1.3)
Infection 9 (11.3)
Relapse 26 (33)
Other† 1 (1.3)
Total 39 (49)
*Values in parentheses are percentage of all patients.
†Drug (narcotic) overdose.
Figure 1. OS of the good-risk and the poor-risk diagnostic groups of patients as determined by KM technique.
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poor-risk patients undergoing HLA-matched sibling PBSC
transplantation after fractionated TBI (1225 cGy) and
chemotherapy, Brown et al. reported 2-year DFS and OS
were 30% and 34%, respectively [30]. For good-risk
patients undergoing HLA-matched sibling BMT after frac-
tionated TBI (1200 cGy at 6-7 cGy/min) and cyclophos-
phamide, Clift et al. reported the 3-year DFS and OS of
AML patients were 58% and 65%, respectively [23],
whereas the 4-year DFS and OS of the CML patients were
58% and 60%, respectively [35]. In a randomized trial of
HLA-identical sibling PBSC transplantation versus BMT
after conventional myeloablative regimens, the 2-year over-
all survivals were 75% and 72% (P = .63), respectively, in
good-risk patients and 57% and 33% (P = .04), respectively,
in poor-risk patients [2]. However, controlled clinical trials
will be required to properly compare the survival outcome
of allogeneic transplantation patients conditioned with this
low-dose TBI regimen with the outcome of a conventional
TBI-based regimen.
In the early 1990s, 2 other groups reported the outcomes
of allogeneic BMT patients conditioned with single-dose
TBI-based regimens that incorporated the high-dose-rate
strategy and used a lower-than-standard TBI dose. Fyles
et al. treated leukemia patients with single-dose TBI (500 cGy
at a median dose rate of 58 cGy/min) plus (various) chemo-
therapy followed by allogeneic BMT and reported event-
free survival of 43% at 5 years for good-risk patients and
15% at 5 years for poor-risk patients [7]. In a nonrandom-
ized study, Kim et al. observed that relapse-free survival
and survival with AML in ﬁrst CR among patients condi-
tioned with single-dose TBI (750 cGy at 26 cGy/min)
and cyclophosphamide were similar to the rates among
patients given fractionated TBI (1320 cGy in 8 fractions at
10 cGy/min) and cyclophosphamide [43]. The reports by
Kim and Fyles demonstrated the feasibility of a low-dose,
high-dose-rate, single-exposure TBI-based conditioning
regimen for donor transplantation. Along with observations
of dog models [3-6], these reports inspired us to develop this
low-intensity myeloablative conditioning regimen. How-
ever, important differences exist between the results of these
human studies and our ﬁndings. Both previous studies pre-
dated the cyclosporine era [7,43]. Our study was unique by
virtue of the TBI prescription (550 cGy at 30 cGy/min),
careful documentation of the rate and durability of donor
cell engraftment by current techniques, use of mobilized
PBSCs (versus BM) and cyclosporine, and the uniform con-
ditioning regimen and supportive care of all patients.
The curative potential of allogeneic transplantation is
due to the combined effect of the conditioning regimen and
the graft-versus-leukemia effect of durably engrafted donor
lymphoid cells. To improve outcomes of donor transplanta-
tion, lower intensity, less toxic conditioning regimens must
result in a reduction in TRM not offset by increased relapse
risk. In this study, we observed that low-dose (550 cGy)
single-exposure TBI given at a high dose rate (30 cGy/min)
along with cyclophosphamide resulted in consistent early
and durable engraftment of HLA-matched related-donor
PBSCs and no graft failure. Fatal organ toxicity occurred in
only 2.5% of patients, and the TRM through at least 2 years
of follow-up of good-risk patients was only 7%. The 3-year
DFS of 77% in good-risk patients and 34% in poor-risk
patients compares favorably with that observed with con-
ventional myeloablative conditioning regimens. The TRM
and risk of fatal organ toxicity observed with this regimen
were similar to those reported for nonmyeloablative regi-
mens. The relapse risk was comparable with that of mye-
loablative regimens. Although patients remain at risk of
relapse and death, the data from this clinical trial suggest
that this low-dose TBI-based conditioning regimen for
donor transplantation was associated with a low risk of
TRM and fatal organ toxicity, which did not occur at the
expense of a greater risk of early disease relapse.
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